We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Specialty and GLP-1 Momentum Support Cencora's Q4 Results?
Read MoreHide Full Article
Key Takeaways
COR's Q4 revenues are estimated at $83.16B, up 5.2%, with EPS seen rising 13.5% to $3.79.
COR's U.S. strength in specialty drugs offsets international softness and moderating GLP-1 growth.
COR's RCA integration and OneOncology investments are expected to lift annual operating income.
Cencora (COR - Free Report) is slated to report fourth-quarter fiscal 2025 results on Nov. 5, before market open.
In the last reported quarter, the company delivered an earnings surprise of 5.82%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.19%.
Cencora’s Q4 Estimates
The Zacks Consensus Estimate for revenues is pegged at $83.16 billion, up 5.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $3.79 per share, indicating an improvement of 13.5% from the prior-year quarter’s figure.
Our model estimate for total revenues and adjusted EPS is pegged at $83.19 billion and $3.79, respectively.
Factors to Consider Before COR Reports
Cencora’s fiscal fourth-quarter 2025 results are likely to reflect continued momentum in its U.S. Healthcare Solutions business, partially offset by lingering softness in international operations. The pharmaceutical distributor’s third-quarter earnings topped expectations with 20% EPS growth, supported by strong specialty distribution trends and the recent Retina Consultants of America acquisition, which boosted both scale and margins.
The fourth-quarter performance is expected to have remained solid, albeit with moderating growth trends. U.S. segment revenues should have benefited from resilient pharmaceutical utilization and strong specialty demand across physician practices and health systems, especially in retina and oncology. However, management has guided for growth of approximately 9% as GLP-1 drug sales, though still expanding at a double-digit clip, are likely to have decelerated from prior quarters.
The loss of a large oncology customer following M&A activity and the exit of a high-revenue but low-margin grocery customer are also likely to have weighed on top-line expansion. Our model estimates US Healthcare Solutions segment sales to be $73.98 billion for fiscal fourth-quarter, implying 5.2% growth.
Internationally, the performance might have continued to face headwinds from weakness in the higher-margin global specialty logistics and consulting businesses, though sequential improvement and favorable currency trends must have helped stabilize margins. Integration of RCA and investments in OneOncology are expected to have supported operating income growth of around 15-16% for the year, with U.S. operating income advancing more than 20%. Our model estimates International segment sales to be $8 billion for fiscal fourth-quarter, implying 8.3% growth.
Our proven model predicts an earnings beat for Cencora this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($3.80 per share) and the Zacks Consensus Estimate ($3.79), is +0.31%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Solventum Corporation (SOLV - Free Report) has an Earnings ESP of +0.88% and a Zacks Rank #1 at present. The company is set to release third-quarter 2025 results on Nov. 6.
SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%. According to the Zacks Consensus Estimate, SOLV’s third-quarter EPS is expected to decline 12.8% from the year-ago reported figure.
McKesson (MCK - Free Report) has an Earnings ESP of +1.72% and a Zacks Rank #1 at present. The company is slated to release second-quarter fiscal 2026 results on Nov. 5.
MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.50%. According to the Zacks Consensus Estimate, MCK’s fiscal second-quarter EPS is expected to gain 26.2% from the year-ago reported figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +1.69% and a Zacks Rank #3 at present. The company is set to release third-quarter 2025 results on Nov. 6.
GMED’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 10.82%. According to the Zacks Consensus Estimate, GMED’s third-quarter EPS is expected to decline 6% from the year-ago reported figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Specialty and GLP-1 Momentum Support Cencora's Q4 Results?
Key Takeaways
Cencora (COR - Free Report) is slated to report fourth-quarter fiscal 2025 results on Nov. 5, before market open.
In the last reported quarter, the company delivered an earnings surprise of 5.82%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.19%.
Cencora’s Q4 Estimates
The Zacks Consensus Estimate for revenues is pegged at $83.16 billion, up 5.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $3.79 per share, indicating an improvement of 13.5% from the prior-year quarter’s figure.
Our model estimate for total revenues and adjusted EPS is pegged at $83.19 billion and $3.79, respectively.
Factors to Consider Before COR Reports
Cencora’s fiscal fourth-quarter 2025 results are likely to reflect continued momentum in its U.S. Healthcare Solutions business, partially offset by lingering softness in international operations. The pharmaceutical distributor’s third-quarter earnings topped expectations with 20% EPS growth, supported by strong specialty distribution trends and the recent Retina Consultants of America acquisition, which boosted both scale and margins.
The fourth-quarter performance is expected to have remained solid, albeit with moderating growth trends. U.S. segment revenues should have benefited from resilient pharmaceutical utilization and strong specialty demand across physician practices and health systems, especially in retina and oncology. However, management has guided for growth of approximately 9% as GLP-1 drug sales, though still expanding at a double-digit clip, are likely to have decelerated from prior quarters.
The loss of a large oncology customer following M&A activity and the exit of a high-revenue but low-margin grocery customer are also likely to have weighed on top-line expansion. Our model estimates US Healthcare Solutions segment sales to be $73.98 billion for fiscal fourth-quarter, implying 5.2% growth.
Internationally, the performance might have continued to face headwinds from weakness in the higher-margin global specialty logistics and consulting businesses, though sequential improvement and favorable currency trends must have helped stabilize margins. Integration of RCA and investments in OneOncology are expected to have supported operating income growth of around 15-16% for the year, with U.S. operating income advancing more than 20%. Our model estimates International segment sales to be $8 billion for fiscal fourth-quarter, implying 8.3% growth.
Cencora, Inc. Price and EPS Surprise
Cencora, Inc. price-eps-surprise | Cencora, Inc. Quote
Earnings Beat Likely
Our proven model predicts an earnings beat for Cencora this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($3.80 per share) and the Zacks Consensus Estimate ($3.79), is +0.31%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: COR carries a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks Worth a Look
Solventum Corporation (SOLV - Free Report) has an Earnings ESP of +0.88% and a Zacks Rank #1 at present. The company is set to release third-quarter 2025 results on Nov. 6.
SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%. According to the Zacks Consensus Estimate, SOLV’s third-quarter EPS is expected to decline 12.8% from the year-ago reported figure.
McKesson (MCK - Free Report) has an Earnings ESP of +1.72% and a Zacks Rank #1 at present. The company is slated to release second-quarter fiscal 2026 results on Nov. 5.
MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.50%. According to the Zacks Consensus Estimate, MCK’s fiscal second-quarter EPS is expected to gain 26.2% from the year-ago reported figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +1.69% and a Zacks Rank #3 at present. The company is set to release third-quarter 2025 results on Nov. 6.
GMED’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 10.82%. According to the Zacks Consensus Estimate, GMED’s third-quarter EPS is expected to decline 6% from the year-ago reported figure.